India lifts price caps on innovative and orphan drugs; major fillip for Big Pharma

5 January 2019

The Indian government has decided to keep its hands off the pricing of new drugs. New legislation announced on January 4, 2019, is set to remove price restrictions on new and innovative drugs developed by foreign pharmaceutical companies for the first five years, reports The Pharma Letter’s India correspondent.

In a rider, the government notification states the provisions of the Drug Price Control Order (DPCO) 2013 will not apply to drugs for treating orphan diseases as decided by the Ministry of Health and Family Welfare.

The move is set to give Indian patients access to drugs that are currently only available outside the country. These include orphan drugs that are used for treating rare medical conditions.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK